Aniebrys Marrero
Spanish National Research Council
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Aniebrys Marrero.
Journal of Biological Chemistry | 2003
Raquel García-Castellanos; Aniebrys Marrero; Goretti Mallorquí-Fernández; Jan Potempa; Miquel Coll; F. Xavier Gomis-Rüth
Methicillin-resistant Staphylococcus aureus is the main cause of nosocomial and community-onset infections that affect millions of people worldwide. Some methicillin-resistant Staphylococcus aureus infections have become essentially untreatable by β-lactams because of acquired molecular machineries enabling antibiotic resistance. Evasion from methicillin challenge is mainly achieved by the synthesis of a penicillin-binding protein of low affinity for antibiotics, MecA, that replaces regular penicillin-binding proteins in cell wall turnover when these have been inactivated by antibiotics. MecA synthesis is regulated by a signal transduction system consisting of the sensor/transducer MecR1 and the 14-kDa transcriptional repressor MecI (also known as methicillin repressor) that constitutively blocks mecA transcription. The three-dimensional structure of MecI reveals a dimer of two independent winged helix domains, each of which binds a palindromic DNA-operator half site, and two intimately intertwining dimerization domains of novel spiral staircase architecture, held together by a hydrophobic core. Limited proteolytic cleavage by cognate MecR1 within the dimerization domains results in loss of dimer interaction surface, dissociation, and repressor release, which triggers MecA synthesis. Structural information on components of the MecA regulatory pathway, in particular on methicillin repressor, the ultimate transcriptional trigger of mecA-encoded methicillin resistance, is expected to lead to the development of new antimicrobial drugs.
Journal of Biological Chemistry | 2011
T.O Botelho; Tibisay Guevara; Aniebrys Marrero; P Arede; Viviana S. Fluxa; Jean-Louis Reymond; D.C Oliveira; F.X. Gomis-Ruth
HmrA is an antibiotic resistance factor of methicillin-resistant Staphylococcus aureus. Molecular analysis of this protein revealed that it is not a muramidase or β-lactamase but a nonspecific double-zinc endopeptidase consisting of a catalytic domain and an inserted oligomerization domain, which probably undergo a relative interdomain hinge rotation upon substrate binding. The active-site cleft is located at the domain interface. Four HmrA protomers assemble to a large ∼170-kDa homotetrameric complex of 125 Å. All four active sites are fully accessible and ∼50–70 Å apart, far enough apart to act on a large meshwork substrate independently but simultaneously. In vivo studies with four S. aureus strains of variable resistance levels revealed that the extracellular addition of HmrA protects against loss of viability in the presence of oxacillin and that this protection depends on proteolytic activity. All of these results indicate that HmrA is a peptidase that participates in resistance mechanisms in vivo in the presence of β-lactams. Furthermore, our results have implications for most S. aureus strains of known genomic sequences and several other cocci and bacilli, which harbor close orthologs. This suggests that HmrA may be a new widespread antibiotic resistance factor in bacteria.
Biological Chemistry | 2007
Cynthia Tallant; Raquel García-Castellanos; Aniebrys Marrero; Francesc Canals; Yongzheng Yang; Jean-Louis Reymond; Maria Solà; Ulrich Baumann; F. Xavier Gomis-Rüth
Abstract Human growth and development are conditioned by insulin-like growth factors (IGFs), which have also implications in pathology. Most IGF molecules are sequestered by IGF-binding proteins (IGFBPs) so that exertion of IGF activity requires disturbance of these complexes. This is achieved by proteolysis mediated by IGFBP proteases, among which the best characterised is human PAPP-A, the first member of the pappalysin family of metzincins. We have previously identified and studied the only archaeal homologue found to date, Methanosarcina acetivorans ulilysin. This is a proteolytically functional enzyme encompassing a pappalysin catalytic domain and a pro-domain involved in maintenance of latency of the zymogen, proulilysin. Once activated, the protein hydrolyses IGFBP-2 to -6 and insulin chain β in vitro. We report here that ulilysin is also active against several other substrates, viz (azo)casein, azoalbumin, and extracellular matrix components. Ulilysin has gelatinolytic but not collagenolytic activity. Moreover, the proteolysis-resistant skeletal proteins actin and elastin are also cleaved, as is fibrinogen, but not plasmin and α1-antitrypsin from the blood coagulation cascade. Ulilysin develops optimal activity at pH 7.5 and strictly requires peptide bonds preceding an arginine residue, as determined by means of a novel fluorescence resonance energy transfer assay, thus pointing to biotechnological applications as an enzyme complementary to trypsin.
Biological Chemistry | 2017
Theodoros Goulas; Irene Garcia-Ferrer; Aniebrys Marrero; Laura Marino-Puertas; Stéphane Duquerroy; F. Xavier Gomis-Rüth
Abstract Peptidases must be exquisitely regulated to prevent erroneous cleavage and one control is provided by protein inhibitors. These are usually specific for particular peptidases or families and sterically block the active-site cleft of target enzymes using lock-and-key mechanisms. In contrast, members of the +1400-residue multi-domain α2-macroglobulin inhibitor family (α2Ms) are directed against a broad spectrum of endopeptidases of disparate specificities and catalytic types, and they inhibit their targets without disturbing their active sites. This is achieved by irreversible trap mechanisms resulting from large conformational rearrangement upon cleavage in a promiscuous bait region through the prey endopeptidase. After decades of research, high-resolution structural details of these mechanisms have begun to emerge for tetrameric and monomeric α2Ms, which use ‘Venus-flytrap’ and ‘snap-trap’ mechanisms, respectively. In the former, represented by archetypal human α2M, inhibition is exerted through physical entrapment in a large cage, in which preys are still active against small substrates and inhibitors that can enter the cage through several apertures. In the latter, represented by a bacterial α2M from Escherichia coli, covalent linkage and steric hindrance of the prey inhibit activity, but only against very large substrates.
Biochimica et Biophysica Acta | 2010
Cynthia Tallant; Aniebrys Marrero; F. Xavier Gomis-Rüth
Journal of Biological Chemistry | 2004
Raquel García-Castellanos; Goretti Mallorquí-Fernández; Aniebrys Marrero; Jan Potempa; Miquel Coll; F.X. Gomis-Ruth
Angewandte Chemie | 2012
Aniebrys Marrero; Stéphane Duquerroy; Stefano Trapani; Theodoros Goulas; Tibisay Guevara; Gregers R. Andersen; Jorge Navaza; F. Xavier Gomis-Rüth
Biochemistry | 2007
Àlex Bayés; Daniel Fernández; Maria Solà; Aniebrys Marrero; Sonia García-Piqué; Francesc X. Avilés; Josep Vendrell; F. Xavier Gomis-Rüth
Fems Microbiology Letters | 2004
Goretti Mallorquí-Fernández; Aniebrys Marrero; Sonia García-Piqué; Raquel García-Castellanos; F. Xavier Gomis-Rüth
Journal of Molecular Biology | 2006
Aniebrys Marrero; Goretti Mallorquí-Fernández; Tibisay Guevara; Raquel García-Castellanos; F. Xavier Gomis-Rüth